• About us
• Contact

Advertisement

Organisation › Details

Euronext (Group)

Euronext is the leading pan-European exchange in the Eurozone with nearly 1,300 listed issuers worth close to €3.6 trillion in market capitalisation as of end December 2017, an unmatched blue chip franchise consisting of 24 issuers in the Morningstar® Eurozone 50 Index? and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM (formerly known as Alternext) and Euronext AccessTM (formerly known as the Free Market). *

 

	Industry	financial services
	Person	Boujnah, Stéphane (Euronext 201711 CEO)
	Region	Amsterdam
	Country	Netherlands
	Street	5 Beursplein
	City	n. a. Amsterdam
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	532,300,000 (revenue, consolidated (2017) 2017-12-31)
	Profit	241,300,000 (2017-12-31)
	Cash	187,800,000 (2017-12-31)
		* Document for »About Section«: Euronext N.V.. (2/19/18). "Press Release: Euronext Publishes Full Year 2017 Results". Amsterdam, Brussels, et al..
		Record changed: 2024-02-12

Advertisement

More documents for Euronext (Group)

• [1] Euronext N.V.. (4/25/22). "Press Release: BenevolentAI Lists on Euronext Amsterdam. Listed Following Business Combination with Odyssey Acquisition S.A.". Amsterdam....
• [2] BenevolentAI. (4/25/22). "Press Release: BenevolentAI Begins Trading On Euronext Amsterdam". London....
• [3] Euronext N.V.. (11/18/21). "Press Release: European Healthcare Acquisition & Growth Company B.V (EHC) Lists on Euronext Amsterdam". Amsterdam....
• [4] Euronext N.V.. (11/2/21). "Press Release: Acticor Biotech Lists on Euronext Growth Paris". Paris....
• [5] Hyloris Pharmaceuticals S.A.. (6/17/20). "Press Release: Hyloris Pharmaceuticals Launches Its Initial Public Offering on Euronext Brussels [Not for US, AU, CA, CH, IL, JP or ZA]". Liège....
• [6] Hyloris Pharmaceuticals S.A.. (6/3/20). "Press Release: Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels [Not for US, AU, CA, CH, IL, JP or ZA]". Liège....
• [7] ImmuPharma plc. (12/19/19). "Press Release: ImmuPharma Lists on Euronext Growth Brussels". Brussels....
• [8] Themis Bioscience N.V.. (11/8/18). "Press Release: Themis Bioscience Postpones Its Listing on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
• [9] Themis Bioscience N.V.. (10/29/18). "Press Release: Themis Bioscience Launches its Initial Public Offering on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
• [10] Euronext N.V.. (10/8/18). "Press Release: Medincell Lists on Euronext Paris. €30 Million Raised, Market Capitalisation €144 Million". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.